Vertex to Announce Second Quarter 2024 Financial Results on August 1
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.43% on an annualized basis producing an average annual return of 19.36%. Currently, Vertex Pharmaceuticals
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): EVP and CMO Carmen Bozic Sells 2,280 Shares
On June 26, 2024, Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 2,280 shares of the company.
Vertex Pharmaceuticals(VRTX.US) Officer Sells US$1.08 Million in Common Stock
$Vertex Pharmaceuticals(VRTX.US)$ Officer Bozic Carmen sold 2,280 shares of common stock on Jun 26, 2024 at an average price of $471.72 for a total value of $1.08 million.Source: Announcement What is
Wells Fargo Updated Its Signature Picks, With Vertex Pharma and AvalonBay as Adds
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
Redburn Atlantic Initiates Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $545
Redburn Atlantic analyst Steve Chesney initiates coverage on $Vertex Pharmaceuticals(VRTX.US)$ with a buy rating, and sets the target price at $545.According to TipRanks data, the analyst has a succes
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target
Vertex Pharmaceuticals (VRTX) has an average outperform rating and a price target range of $325 to $577, according to analysts polled by Capital IQ.
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals's (NYSE:VRTX) short percent of float has risen 15.75% since its last report. The company recently reported that it has 4.35 million shares sold short, which is 1.69% of all regu
Gain Rotation Out of Semis Is Feeding Into Other Parts of the Market - Argus
Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 1.08 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 26, $Vertex Pharmaceuticals(VRTX.US)$ Officer Bozic Carmen intends to sell 2,280 shares of its common stock on Jun 26, with a total market value of approximately $1.08 mill
Express News | Vertex Pharmaceuticals Inc : Piper Sandler Raises Target Price to $500 From $456
Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Maxim Group analyst Naz Rahman maintains $Vertex Pharmaceuticals(VRTX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 27.7% and a total average return of -15.1% o
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating
Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $577, according to analysts polled by Capital IQ. Price: 473.50, Change: -1.45, Percent Change:
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing.
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $474.95, marking a +1.33% move from the previous day.
Vertex Pharmaceutical Incorporated. (VRTX): Analysts Are Bullish on This Healthcare Stock's Strong Financial Performance in Q1
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $550
BofA Securities analyst Alexandria Hammond maintains $Vertex Pharmaceuticals(VRTX.US)$ with a buy rating, and maintains the target price at $550.According to TipRanks data, the analyst has a success r